IN THE NEWS

BOTHELL, WA and BALTIMORE – Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products, and US Lacrosse, the national governing body for men’s and women’s lacrosse, announced today that they have formed a strategic alliance to increase the likelihood of surviving sudden cardiac arrest (SCA) during a lacrosse game.  The alliance will accomplish this by increasing the awareness and availability of Powerheart^® automated external defibrillators (AEDs) to US Lacrosse members and affiliated programs. 

AEDs are an effective response to commotio cordis, a rare but potentially catastrophic phenomenon that can cause SCA in athletes. Commotio cordis occurs when a person receives a blunt blow to the area of the chest directly over the heart during a precise moment of the heart’s cycle, causing SCA.   The blow need not be severe; in fact, commotio cordis can be caused by a relatively mild impact.

According to US Lacrosse, at least five lacrosse players are believed to have died during competition as a result of SCA caused by commotio cordis since 1999, though it has afflicted many more people in a variety of organized athletic events, recreational play and non-sports activities. The US Commotio Cordis Registry has received more than 180 reported cases of commotio cordis since it began keeping records in 1996. In addition to commotio cordis, US Lacrosse notes that other serious cardiac events have struck lacrosse coaches, officials, players and fans during competition.

“Lacrosse is the fastest-growing sport in the United States,” said Steve Stenersen, Executive Director of US Lacrosse. “Injury research shows that lacrosse is a relatively safe sport to play, but the risk of catastrophic injury still exists, as it does in every sport.  In the rare case of a commotio cordis episode, or if SCA should afflict a spectator or official, the prompt and proper use of an AED greatly increases the odds of the victim’s survival. We encourage lacrosse organizations around the country to purchase AEDs as an additional step in the quest to provide the safest possible environment for their players, coaches, officials and spectators. This proactive step has the potential to save lives.”

As a result of the partnership, Cardiac Science will provide automated external defibrillators at preferred prices to members of US Lacrosse. The Company has also equipped the USL headquarters in Baltimore with an AED and is providing related training and program management services.  Most importantly, the two organizations have committed to working together to achieve greater awareness of SCA and the importance of accessible defibrillation among the rapidly growing body of lacrosse players, coaches, officials and fans, nationwide.   

“Tragically, many of us know of a friend or family member who has suffered an unexpected SCA,” said Mike Brode, Cardiac Science Director for Strategic Business. “We applaud US Lacrosse’s proactive step towards raising awareness of the value of having AEDs at the sidelines of its events across the country, ensuring that potentially life saving defibrillation is on-hand in case the unexpected should occur.” 

For more information on AEDs and the partnership between U.S. Lacrosse and Cardiac Science, please visit www.uslacrosse.org/safety/aed.phtml or www.cardiacsciencepartners.com/USL/.

About US Lacrosse

US Lacrosse, a 501^©(3) corporation, is the national governing body for men’s and women’s lacrosse. To learn more about the organization, please visit the Web site at www.uslacrosse.org.

About Powerheart

Powerheart brand automated external defibrillators provide reliable, safe, and easy to use cardiac monitoring and defibrillation technology. Powerheart AEDs feature RHYTHMx^TM software which detects abnormal heart rhythms, determines whether they are life-threatening, and only delivers a shock when needed. Powerheart AEDs also feature the patented RescueReady^® technology, which automatically tests the device on a frequent basis to ensure continued functionality. Powerheart’s STAR^® Biphasic Waveform Technology provides levels of escalating energy customized to the patient.  Powerheart AEDs are used by hospitals, police and fire departments, as well as many public access facilities including major corporations, public agencies, airlines and airports, arenas, schools, hotels, casinos and consumers. For more information about Powerheart, go to www.powerheart.com.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif